Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches
Colorectal cancer (CRC) is a significant health issue globally, affecting approximately 10 % of the world's population. The prevalence of CRC highlights the need for effective treatments and prevention strategies. The current therapeutic option, such as chemotherapy, has significant side effect...
Gespeichert in:
Veröffentlicht in: | Computers in biology and medicine 2024-11, Vol.182, p.109136, Article 109136 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 109136 |
container_title | Computers in biology and medicine |
container_volume | 182 |
creator | Akash, Shopnil Shanto, S.K. Hasibul Islam Islam, Md. Rezaul Bayil, Imren Afolabi, Samson Olusegun Guendouzi, Abdelkrim Abdellattif, Magda H. Zaki, Magdi E.A. |
description | Colorectal cancer (CRC) is a significant health issue globally, affecting approximately 10 % of the world's population. The prevalence of CRC highlights the need for effective treatments and prevention strategies. The current therapeutic option, such as chemotherapy, has significant side effects. Thus, this study investigated the anticancer properties of Sanguinarine derivatives, an alkaloid found in traditional herbs via chemoinformatic approaches. Six Sanguinarine derivatives were discovered through virtual screening and molecular docking to determine their binding affinities against the mixed lineage kinase (MLK4) protein which is responsible for CRC. All the compounds were found to be more effective than standard drug used for colorectal cancer treatment, with Sanguinarine derivative 11 showing the highest affinity. The stability of the drug was confirmed through molecular dynamics simulations at 500 ns. This suggests that compound 11 has a higher chance of replacing 5-Fluorouracil, which is currently a widely used chemotherapy drug. Before molecular dynamics simulations, the pharmacokinetic and chemical properties of Sanguinarine derivatives were determined using pkCSM server and DFT method, respectively. The results support that compound 11 is a good drug candidate, as evidenced by Lipinski's Rule of Five. Therefore, compound 11 is recommended for further analysis via in vivo and in vitro studies to confirm its efficacy and safety.
Graphical illustration of the studies. [Display omitted]
•This study conducted to analyses the anticancer properties of Sanguinarine derivatives through computational approaches.•Six Sanguinarine derivatives were identified as having the most promising binding affinities among all the derivatives.•These derivatives demonstrated higher binding energies than the standard 5-Fluorouracil and their stability confirmed through molecular dynamics simulations at 500 ns.•All of these compounds appear to have lower toxicity.•None of the compounds violate Lipinski's Rule of Five. |
doi_str_mv | 10.1016/j.compbiomed.2024.109136 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3107157969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010482524012216</els_id><sourcerecordid>3107157969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1928-7995da1590c51852f44f6314a68bafcca35af581f9973347791808a2787395c23</originalsourceid><addsrcrecordid>eNqFkUtPAyEUhYnR2Fr9C4bEjZupPAdYan3GGje6NIRSpqWZDhVmTPz3MmkbEzeygXA_7rmcAwDEaIwRLq9WYxvWm5kPazcfE0RYvlaYlgdgiKVQBeKUHYIhQhgVTBI-ACcprRBCDFF0DAZUESXzGoKPW59s-HLxG4YKNvlUw5fpM4O-WfqZb0NM0CyMb1ILbahDdLY1NbSmsS7CdhlDt1jCfpquNa0PTS6azSYGY5cunYKjytTJne32EXi_v3ubPBbT14enyfW0sFgRWQil-NxgrpDlWHJSMVaVFDNTypmprDWUm4pLXCklKGVCKCyRNERIQRW3hI7A5bZvFv7sXGr1On_L1bVpXOiSphgJzIUqVUYv_qCr0MU8dk8RnhUk6xvKLWVjSCm6Sm-iX5v4rTHSfQR6pX8j0H0EehtBfnq-E-hmfW3_cO95Bm62gMuOfHkXdbLeZT_nvndXz4P_X-UHnQCbww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3125997842</pqid></control><display><type>article</type><title>Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Akash, Shopnil ; Shanto, S.K. Hasibul Islam ; Islam, Md. Rezaul ; Bayil, Imren ; Afolabi, Samson Olusegun ; Guendouzi, Abdelkrim ; Abdellattif, Magda H. ; Zaki, Magdi E.A.</creator><creatorcontrib>Akash, Shopnil ; Shanto, S.K. Hasibul Islam ; Islam, Md. Rezaul ; Bayil, Imren ; Afolabi, Samson Olusegun ; Guendouzi, Abdelkrim ; Abdellattif, Magda H. ; Zaki, Magdi E.A.</creatorcontrib><description>Colorectal cancer (CRC) is a significant health issue globally, affecting approximately 10 % of the world's population. The prevalence of CRC highlights the need for effective treatments and prevention strategies. The current therapeutic option, such as chemotherapy, has significant side effects. Thus, this study investigated the anticancer properties of Sanguinarine derivatives, an alkaloid found in traditional herbs via chemoinformatic approaches. Six Sanguinarine derivatives were discovered through virtual screening and molecular docking to determine their binding affinities against the mixed lineage kinase (MLK4) protein which is responsible for CRC. All the compounds were found to be more effective than standard drug used for colorectal cancer treatment, with Sanguinarine derivative 11 showing the highest affinity. The stability of the drug was confirmed through molecular dynamics simulations at 500 ns. This suggests that compound 11 has a higher chance of replacing 5-Fluorouracil, which is currently a widely used chemotherapy drug. Before molecular dynamics simulations, the pharmacokinetic and chemical properties of Sanguinarine derivatives were determined using pkCSM server and DFT method, respectively. The results support that compound 11 is a good drug candidate, as evidenced by Lipinski's Rule of Five. Therefore, compound 11 is recommended for further analysis via in vivo and in vitro studies to confirm its efficacy and safety.
Graphical illustration of the studies. [Display omitted]
•This study conducted to analyses the anticancer properties of Sanguinarine derivatives through computational approaches.•Six Sanguinarine derivatives were identified as having the most promising binding affinities among all the derivatives.•These derivatives demonstrated higher binding energies than the standard 5-Fluorouracil and their stability confirmed through molecular dynamics simulations at 500 ns.•All of these compounds appear to have lower toxicity.•None of the compounds violate Lipinski's Rule of Five.</description><identifier>ISSN: 0010-4825</identifier><identifier>ISSN: 1879-0534</identifier><identifier>EISSN: 1879-0534</identifier><identifier>DOI: 10.1016/j.compbiomed.2024.109136</identifier><identifier>PMID: 39298888</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>5-Fluorouracil ; Affinity ; Anticancer properties ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Benzophenanthridines - chemistry ; Benzophenanthridines - pharmacology ; Bioavailability ; Cancer therapies ; Chemical properties ; Chemotherapy ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - metabolism ; Drug development ; Drug Discovery ; Effectiveness ; Humans ; Immunotherapy ; In vivo methods and tests ; Inflammatory bowel disease ; Isoquinolines - chemistry ; Isoquinolines - pharmacology ; Isoquinolines - therapeutic use ; Kinases ; Ligands ; MAP kinase ; Medical prognosis ; Mixed lineage kinases ; Molecular docking ; Molecular Docking Simulation ; Molecular dynamics ; Molecular Dynamics Simulation ; Optimization ; Patients ; Pharmacokinetics ; Protein kinase C ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacology ; Proteins ; Sanguinarine ; Sanguinarine derivatives ; Side effects ; Simulation</subject><ispartof>Computers in biology and medicine, 2024-11, Vol.182, p.109136, Article 109136</ispartof><rights>2024 Elsevier Ltd</rights><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><rights>2024. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1928-7995da1590c51852f44f6314a68bafcca35af581f9973347791808a2787395c23</cites><orcidid>0000-0003-1751-705X ; 0000-0001-8613-6539 ; 0000-0002-6174-5044</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0010482524012216$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39298888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Akash, Shopnil</creatorcontrib><creatorcontrib>Shanto, S.K. Hasibul Islam</creatorcontrib><creatorcontrib>Islam, Md. Rezaul</creatorcontrib><creatorcontrib>Bayil, Imren</creatorcontrib><creatorcontrib>Afolabi, Samson Olusegun</creatorcontrib><creatorcontrib>Guendouzi, Abdelkrim</creatorcontrib><creatorcontrib>Abdellattif, Magda H.</creatorcontrib><creatorcontrib>Zaki, Magdi E.A.</creatorcontrib><title>Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches</title><title>Computers in biology and medicine</title><addtitle>Comput Biol Med</addtitle><description>Colorectal cancer (CRC) is a significant health issue globally, affecting approximately 10 % of the world's population. The prevalence of CRC highlights the need for effective treatments and prevention strategies. The current therapeutic option, such as chemotherapy, has significant side effects. Thus, this study investigated the anticancer properties of Sanguinarine derivatives, an alkaloid found in traditional herbs via chemoinformatic approaches. Six Sanguinarine derivatives were discovered through virtual screening and molecular docking to determine their binding affinities against the mixed lineage kinase (MLK4) protein which is responsible for CRC. All the compounds were found to be more effective than standard drug used for colorectal cancer treatment, with Sanguinarine derivative 11 showing the highest affinity. The stability of the drug was confirmed through molecular dynamics simulations at 500 ns. This suggests that compound 11 has a higher chance of replacing 5-Fluorouracil, which is currently a widely used chemotherapy drug. Before molecular dynamics simulations, the pharmacokinetic and chemical properties of Sanguinarine derivatives were determined using pkCSM server and DFT method, respectively. The results support that compound 11 is a good drug candidate, as evidenced by Lipinski's Rule of Five. Therefore, compound 11 is recommended for further analysis via in vivo and in vitro studies to confirm its efficacy and safety.
Graphical illustration of the studies. [Display omitted]
•This study conducted to analyses the anticancer properties of Sanguinarine derivatives through computational approaches.•Six Sanguinarine derivatives were identified as having the most promising binding affinities among all the derivatives.•These derivatives demonstrated higher binding energies than the standard 5-Fluorouracil and their stability confirmed through molecular dynamics simulations at 500 ns.•All of these compounds appear to have lower toxicity.•None of the compounds violate Lipinski's Rule of Five.</description><subject>5-Fluorouracil</subject><subject>Affinity</subject><subject>Anticancer properties</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Benzophenanthridines - chemistry</subject><subject>Benzophenanthridines - pharmacology</subject><subject>Bioavailability</subject><subject>Cancer therapies</subject><subject>Chemical properties</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Drug development</subject><subject>Drug Discovery</subject><subject>Effectiveness</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>In vivo methods and tests</subject><subject>Inflammatory bowel disease</subject><subject>Isoquinolines - chemistry</subject><subject>Isoquinolines - pharmacology</subject><subject>Isoquinolines - therapeutic use</subject><subject>Kinases</subject><subject>Ligands</subject><subject>MAP kinase</subject><subject>Medical prognosis</subject><subject>Mixed lineage kinases</subject><subject>Molecular docking</subject><subject>Molecular Docking Simulation</subject><subject>Molecular dynamics</subject><subject>Molecular Dynamics Simulation</subject><subject>Optimization</subject><subject>Patients</subject><subject>Pharmacokinetics</subject><subject>Protein kinase C</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Proteins</subject><subject>Sanguinarine</subject><subject>Sanguinarine derivatives</subject><subject>Side effects</subject><subject>Simulation</subject><issn>0010-4825</issn><issn>1879-0534</issn><issn>1879-0534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtPAyEUhYnR2Fr9C4bEjZupPAdYan3GGje6NIRSpqWZDhVmTPz3MmkbEzeygXA_7rmcAwDEaIwRLq9WYxvWm5kPazcfE0RYvlaYlgdgiKVQBeKUHYIhQhgVTBI-ACcprRBCDFF0DAZUESXzGoKPW59s-HLxG4YKNvlUw5fpM4O-WfqZb0NM0CyMb1ILbahDdLY1NbSmsS7CdhlDt1jCfpquNa0PTS6azSYGY5cunYKjytTJne32EXi_v3ubPBbT14enyfW0sFgRWQil-NxgrpDlWHJSMVaVFDNTypmprDWUm4pLXCklKGVCKCyRNERIQRW3hI7A5bZvFv7sXGr1On_L1bVpXOiSphgJzIUqVUYv_qCr0MU8dk8RnhUk6xvKLWVjSCm6Sm-iX5v4rTHSfQR6pX8j0H0EehtBfnq-E-hmfW3_cO95Bm62gMuOfHkXdbLeZT_nvndXz4P_X-UHnQCbww</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Akash, Shopnil</creator><creator>Shanto, S.K. Hasibul Islam</creator><creator>Islam, Md. Rezaul</creator><creator>Bayil, Imren</creator><creator>Afolabi, Samson Olusegun</creator><creator>Guendouzi, Abdelkrim</creator><creator>Abdellattif, Magda H.</creator><creator>Zaki, Magdi E.A.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>JQ2</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1751-705X</orcidid><orcidid>https://orcid.org/0000-0001-8613-6539</orcidid><orcidid>https://orcid.org/0000-0002-6174-5044</orcidid></search><sort><creationdate>202411</creationdate><title>Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches</title><author>Akash, Shopnil ; Shanto, S.K. Hasibul Islam ; Islam, Md. Rezaul ; Bayil, Imren ; Afolabi, Samson Olusegun ; Guendouzi, Abdelkrim ; Abdellattif, Magda H. ; Zaki, Magdi E.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1928-7995da1590c51852f44f6314a68bafcca35af581f9973347791808a2787395c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>5-Fluorouracil</topic><topic>Affinity</topic><topic>Anticancer properties</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Benzophenanthridines - chemistry</topic><topic>Benzophenanthridines - pharmacology</topic><topic>Bioavailability</topic><topic>Cancer therapies</topic><topic>Chemical properties</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Drug development</topic><topic>Drug Discovery</topic><topic>Effectiveness</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>In vivo methods and tests</topic><topic>Inflammatory bowel disease</topic><topic>Isoquinolines - chemistry</topic><topic>Isoquinolines - pharmacology</topic><topic>Isoquinolines - therapeutic use</topic><topic>Kinases</topic><topic>Ligands</topic><topic>MAP kinase</topic><topic>Medical prognosis</topic><topic>Mixed lineage kinases</topic><topic>Molecular docking</topic><topic>Molecular Docking Simulation</topic><topic>Molecular dynamics</topic><topic>Molecular Dynamics Simulation</topic><topic>Optimization</topic><topic>Patients</topic><topic>Pharmacokinetics</topic><topic>Protein kinase C</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Proteins</topic><topic>Sanguinarine</topic><topic>Sanguinarine derivatives</topic><topic>Side effects</topic><topic>Simulation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Akash, Shopnil</creatorcontrib><creatorcontrib>Shanto, S.K. Hasibul Islam</creatorcontrib><creatorcontrib>Islam, Md. Rezaul</creatorcontrib><creatorcontrib>Bayil, Imren</creatorcontrib><creatorcontrib>Afolabi, Samson Olusegun</creatorcontrib><creatorcontrib>Guendouzi, Abdelkrim</creatorcontrib><creatorcontrib>Abdellattif, Magda H.</creatorcontrib><creatorcontrib>Zaki, Magdi E.A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Computer Science Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Computers in biology and medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Akash, Shopnil</au><au>Shanto, S.K. Hasibul Islam</au><au>Islam, Md. Rezaul</au><au>Bayil, Imren</au><au>Afolabi, Samson Olusegun</au><au>Guendouzi, Abdelkrim</au><au>Abdellattif, Magda H.</au><au>Zaki, Magdi E.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches</atitle><jtitle>Computers in biology and medicine</jtitle><addtitle>Comput Biol Med</addtitle><date>2024-11</date><risdate>2024</risdate><volume>182</volume><spage>109136</spage><pages>109136-</pages><artnum>109136</artnum><issn>0010-4825</issn><issn>1879-0534</issn><eissn>1879-0534</eissn><abstract>Colorectal cancer (CRC) is a significant health issue globally, affecting approximately 10 % of the world's population. The prevalence of CRC highlights the need for effective treatments and prevention strategies. The current therapeutic option, such as chemotherapy, has significant side effects. Thus, this study investigated the anticancer properties of Sanguinarine derivatives, an alkaloid found in traditional herbs via chemoinformatic approaches. Six Sanguinarine derivatives were discovered through virtual screening and molecular docking to determine their binding affinities against the mixed lineage kinase (MLK4) protein which is responsible for CRC. All the compounds were found to be more effective than standard drug used for colorectal cancer treatment, with Sanguinarine derivative 11 showing the highest affinity. The stability of the drug was confirmed through molecular dynamics simulations at 500 ns. This suggests that compound 11 has a higher chance of replacing 5-Fluorouracil, which is currently a widely used chemotherapy drug. Before molecular dynamics simulations, the pharmacokinetic and chemical properties of Sanguinarine derivatives were determined using pkCSM server and DFT method, respectively. The results support that compound 11 is a good drug candidate, as evidenced by Lipinski's Rule of Five. Therefore, compound 11 is recommended for further analysis via in vivo and in vitro studies to confirm its efficacy and safety.
Graphical illustration of the studies. [Display omitted]
•This study conducted to analyses the anticancer properties of Sanguinarine derivatives through computational approaches.•Six Sanguinarine derivatives were identified as having the most promising binding affinities among all the derivatives.•These derivatives demonstrated higher binding energies than the standard 5-Fluorouracil and their stability confirmed through molecular dynamics simulations at 500 ns.•All of these compounds appear to have lower toxicity.•None of the compounds violate Lipinski's Rule of Five.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>39298888</pmid><doi>10.1016/j.compbiomed.2024.109136</doi><orcidid>https://orcid.org/0000-0003-1751-705X</orcidid><orcidid>https://orcid.org/0000-0001-8613-6539</orcidid><orcidid>https://orcid.org/0000-0002-6174-5044</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0010-4825 |
ispartof | Computers in biology and medicine, 2024-11, Vol.182, p.109136, Article 109136 |
issn | 0010-4825 1879-0534 1879-0534 |
language | eng |
recordid | cdi_proquest_miscellaneous_3107157969 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | 5-Fluorouracil Affinity Anticancer properties Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Benzophenanthridines - chemistry Benzophenanthridines - pharmacology Bioavailability Cancer therapies Chemical properties Chemotherapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - metabolism Drug development Drug Discovery Effectiveness Humans Immunotherapy In vivo methods and tests Inflammatory bowel disease Isoquinolines - chemistry Isoquinolines - pharmacology Isoquinolines - therapeutic use Kinases Ligands MAP kinase Medical prognosis Mixed lineage kinases Molecular docking Molecular Docking Simulation Molecular dynamics Molecular Dynamics Simulation Optimization Patients Pharmacokinetics Protein kinase C Protein Kinase Inhibitors - chemistry Protein Kinase Inhibitors - pharmacology Proteins Sanguinarine Sanguinarine derivatives Side effects Simulation |
title | Discovery of novel MLK4 inhibitors against colorectal cancer through computational approaches |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T15%3A23%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20novel%20MLK4%20inhibitors%20against%20colorectal%20cancer%20through%20computational%20approaches&rft.jtitle=Computers%20in%20biology%20and%20medicine&rft.au=Akash,%20Shopnil&rft.date=2024-11&rft.volume=182&rft.spage=109136&rft.pages=109136-&rft.artnum=109136&rft.issn=0010-4825&rft.eissn=1879-0534&rft_id=info:doi/10.1016/j.compbiomed.2024.109136&rft_dat=%3Cproquest_cross%3E3107157969%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3125997842&rft_id=info:pmid/39298888&rft_els_id=S0010482524012216&rfr_iscdi=true |